Growth Hormone Treatment of Short Children Born Small for Gestational Age

Zegher, Francis de

doi:10.1297/cpe.6.supple10_129

Cited by 5 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found that the maximum GH levels during the provocation tests before the start of the GH treatment were not significantly related to the growth response. Two previous studies also found no differences in growth response to GH treatment between SGA children who were GH deficient and those who were not (35,40). In addition, our study showed that neither the IGF-I levels at baseline nor the GH levels during the 24-h plasma GH profile test were significantly related to the growth response.…”

Section: Discussioncontrasting

confidence: 75%

See 1 more Smart Citation

Growth Hormone Treatment in Children with Short Stature Born Small for Gestational Age: 5-Year Results of a Randomized, Double-Blind, Dose-Response Trial¹

Sas

Waal

Mulder

et al. 1999

The Journal of Clinical Endocrinology & Metabolism

View full text Add to dashboard Cite

The growth-promoting effect of continuous GH treatment was evaluated over 5 yr in 79 children with short stature (height SD score, less than -1.88) born small for gestational age (SGA; birth length SD score, less than -1.88). Patients were randomly and blindly assigned to 1 of 2 GH dosage groups (3 vs. 6 IU/m2 body surface-day). GH deficiency was not an exclusion criterium. After 5 yr of GH treatment almost every child had reached a height well within the normal range for healthy Dutch children and in the range of their target height SD score. Only in children who remained prepubertal during the study period was the 5-yr increase in height SD score (HSDS) for chronological age significantly higher in the study group receiving 6 compared to 3 IU GH/m2 x day. Remarkably, the 5-yr increment in HSDS for chronological age was not related to spontaneous GH secretion, maximum GH levels after provocation, or baseline insulin-like growth factor I levels. GH treatment was associated with an acceleration of bone maturation regardless of the GH dose given. The HSDS for bone age and predicted adult height increased significantly. GH treatment was well tolerated. In conclusion, our 5-yr data show that long term continuous GH treatment at a dose of 3 or 6 IU/m2 x day in short children born SGA results in a normalization of height during childhood followed by growth along the target height percentile.

show abstract

Section: Discussioncontrasting

confidence: 75%

“…Comparing our growth results with those of other GHtreated patient groups receiving long term GH treatment, the gain in height in short children born SGA is comparable with that in GHD patients with a GH dose that is slightly higher than the conventional GH dose (2 IU/m 2 ⅐day) (35).…”

Section: Discussionsupporting

confidence: 63%

Growth Hormone Treatment in Children with Short Stature Born Small for Gestational Age: 5-Year Results of a Randomized, Double-Blind, Dose-Response Trial¹

Sas

Waal

Mulder

et al. 1999

The Journal of Clinical Endocrinology & Metabolism

View full text Add to dashboard Cite

show abstract

“…There are several theories to explain their persistent short stature. One suggests that it is the result of a reduced sensitivity for growth factors; another suggests that it might be influenced by intrauterine reprogramming or genetic background (7)(8)(9). Recent studies have demonstrated that 5 yr of GH treatment in short children born SGA results in a normalization of height during childhood (6,10).…”

mentioning

confidence: 99%

Adult Height after Long-Term, Continuous Growth Hormone (GH) Treatment in Short Children Born Small for Gestational Age: Results of a Randomized, Double-Blind, Dose-Response GH Trial

Pareren

Mulder

Houdijk

et al. 2003

The Journal of Clinical Endocrinology & Metabolism

247

192

View full text Add to dashboard Cite

The GH dose-response effect of long-term continuous GH treatment on adult height (AH) was evaluated in 54 short children born small for gestational age (SGA) who were participating in a randomized, double-blind, dose-response trial. Patients were randomly and blindly assigned to treatment with either 3 IU (group A) or 6 IU (group B) GH/m(2).d ( approximately 0.033 or 0.067 mg/kg.d, respectively). The mean (+/-SD) birth length was -3.6 (1.4), the age at the start of the study was 8.1 (1.9) yr, and the height SD score (SDS) at the start of the study -3.0 (0.7). Seventeen of the 54 children were partially GH deficient (stimulated GH peak, 10-20 mU/liter). Fifteen non-GH-treated, non-GH-deficient, short children born SGA, with similar inclusion criteria, served as controls [mean (+/-SD) birth length, -3.3 (1.2); age at start, 7.8 (1.7) yr; height SDS at start, -2.6 (0.5)]. GH treatment resulted in an AH above -2 SDS in 85% of the children after a mean (+/-SD) GH treatment period of 7.8 (1.7) yr. The mean (SD) AH SDS was -1.1 (0.7) for group A and -0.9 (0.8) for group B, resulting from a mean (+/-SD) gain in height SDS of 1.8 (0.7) for group A and 2.1 (0.8) for group B. No significant differences between groups A and B were found for AH SDS (mean difference, 0.3 SDS; 95% confidence interval, -0.2, 0.6; P > 0.2) and gain in height SDS (mean difference, 0.3 SDS; 95% confidence interval, -0.1, 0.7; P > 0.1). When corrected for target height, the mean corrected AH SDS was -0.2 (0.8) for group A and -0.4 (0.9) for group B. The mean (+/-SD) AH SDS of the control group [-2.3 (0.7)] was significantly lower than that of the GH-treated group (P < 0.001). Multiple regression analysis indicated the following predictive variables for AH SDS: target height SDS, height SDS, and chronological age minus bone age (years) at the start of the study. GH dose had no significant effect. In conclusion, long-term continuous GH treatment in short children born SGA without signs of persistent catch-up growth leads to a normalization of AH, even with a GH dose of 3 IU/m(2).d ( approximately 0.033 mg/kg.d).

show abstract

“…Проведя эпианализ результатов 6-летней терапии соматропином 4 рандомизированных многоцентровых исследований, de Zegher F. с коллегами продемонстрировали больший ростовой эффект ГР при применении больших доз: увеличение SDS роста от -3,4 до -0,6 при дозе 0,033 мг/кг/сут; от -4,0 до -0,3 -при 0,067 мг/кг/сут [65]. Различий в ростовом ответе между детьми, имевшими и не имевшими ДГР, получено не было [64,66], что свидетельствует у детей с ЗВУР об отсутствии ассоциации между ростовым ответом и уровнями стимулированного в ходе провокационных тестов СТГ. В более поздних исследованиях получены более скромные результаты, но и они подтвердили эффективность лечения ГР у низкорослых детей с ЗВУР.…”

Section: терапия соматропином у низкорослых детей с звурunclassified

Short stature due to intrauterine growth retardation. Clinical and hormonal-metabolic features, possibilities of growth-stimulating therapy

Nagaeva

2022

Probl Endokrinol (Mosk)

View full text Add to dashboard Cite

The article presents data about short stature due to intrauterine development delay. This type of short stature — separate nosology, unites children born small for gestation age. The majority of them in the first years of life have accelerated growth rates, allowing the child to normalize their weight-growth indicators and catch up in the development of peers. In the absence of an accelerated growth rates, children have a high risk of lagging behind in physical development throughout childhood, achieving low final growth and becoming short adults. In addition, the fact of birth with small body sizes is associated with a number of hormonal and metabolic features, a risk of metabolic syndrome in adult years.It is assumed that the absence of postnatal growth acceleration is due to various damages to the GH-IGF1 axis (partial GH deficiency, partial resistance to GH, partial resistance to IGF1). Growth hormone therapy, initiated early in life, is able to normalize growth rates in childhood and ultimately significantly improve or normalize the final growth of short stature children born small for gestational age.

show abstract

Growth Hormone Treatment of Short Children Born Small for Gestational Age

Cited by 5 publications

References 18 publications

Growth Hormone Treatment in Children with Short Stature Born Small for Gestational Age: 5-Year Results of a Randomized, Double-Blind, Dose-Response Trial¹

Growth Hormone Treatment in Children with Short Stature Born Small for Gestational Age: 5-Year Results of a Randomized, Double-Blind, Dose-Response Trial¹

Adult Height after Long-Term, Continuous Growth Hormone (GH) Treatment in Short Children Born Small for Gestational Age: Results of a Randomized, Double-Blind, Dose-Response GH Trial

Short stature due to intrauterine growth retardation. Clinical and hormonal-metabolic features, possibilities of growth-stimulating therapy

Contact Info

Product

Resources

About

Growth Hormone Treatment of Short Children Born Small for Gestational Age

Cited by 5 publications

References 18 publications

Growth Hormone Treatment in Children with Short Stature Born Small for Gestational Age: 5-Year Results of a Randomized, Double-Blind, Dose-Response Trial1

Growth Hormone Treatment in Children with Short Stature Born Small for Gestational Age: 5-Year Results of a Randomized, Double-Blind, Dose-Response Trial1

Adult Height after Long-Term, Continuous Growth Hormone (GH) Treatment in Short Children Born Small for Gestational Age: Results of a Randomized, Double-Blind, Dose-Response GH Trial

Short stature due to intrauterine growth retardation. Clinical and hormonal-metabolic features, possibilities of growth-stimulating therapy

Contact Info

Product

Resources

About

Growth Hormone Treatment in Children with Short Stature Born Small for Gestational Age: 5-Year Results of a Randomized, Double-Blind, Dose-Response Trial¹

Growth Hormone Treatment in Children with Short Stature Born Small for Gestational Age: 5-Year Results of a Randomized, Double-Blind, Dose-Response Trial¹